These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 7885524

  • 1. Treatment of patients with IVCS and gross oedema and ascites with diuretic combination and ACE-inhibitors: relation to baseline PRA and PAC.
    Van Vliet AA, Kröger R, Dubbelman R, Ten Bokkel-Huinink WW.
    Neth J Med; 1995 Feb; 46(2):62-72. PubMed ID: 7885524
    [Abstract] [Full Text] [Related]

  • 2. Use of piretanide, a new loop diuretic, in cirrhosis with ascites: relationship between the diuretic response and the plasma aldosterone level.
    Arroyo V, Bosch J, Casamitjana R, Cabrera J, Rivera F, Rodés J.
    Gut; 1980 Oct; 21(10):855-9. PubMed ID: 7439805
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of low-dose captopril in addition to furosemide and spironolactone in patients with decompensated liver disease during blunted diuresis.
    van Vliet AA, Hackeng WH, Donker AJ, Meuwissen SG.
    J Hepatol; 1992 May; 15(1-2):40-7. PubMed ID: 1324274
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).
    Am J Cardiol; 1996 Oct 15; 78(8):902-7. PubMed ID: 8888663
    [Abstract] [Full Text] [Related]

  • 5. The effects of treatment with octreotide, diuretics, or both on portal hemodynamics in nonazotemic cirrhotic patients with ascites.
    Kalambokis G, Economou M, Kosta P, Papadimitriou K, Tsianos EV.
    J Clin Gastroenterol; 2006 Apr 15; 40(4):342-6. PubMed ID: 16633107
    [Abstract] [Full Text] [Related]

  • 6. Renin-aldosterone system can respond to furosemide in patients with hyperkalemic hyporeninism.
    Chan R, Sealey JE, Michelis MF, Swan A, Pfaffle AE, Devita MV, Zabetakis PM.
    J Lab Clin Med; 1998 Sep 15; 132(3):229-35. PubMed ID: 9735929
    [Abstract] [Full Text] [Related]

  • 7. [Biological factors influencing response to diuretics in patients with cirrhosis and ascites].
    Lenaerts A, Codden T, Henry JP, Van Cauter J, Meunier JC, Ligny G.
    Gastroenterol Clin Biol; 2001 Mar 15; 25(3):268-72. PubMed ID: 11395674
    [Abstract] [Full Text] [Related]

  • 8. Predictive factors influencing the therapeutic response to diuretic treatment of ascites in nonazotemic cirrhotic patients.
    Ljubicić N, Kujundzić M, Banić M, Vrkljan M.
    Scand J Gastroenterol; 1998 Apr 15; 33(4):441-7. PubMed ID: 9605268
    [Abstract] [Full Text] [Related]

  • 9. Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo.
    Fernández-Esparrach G, Guevara M, Sort P, Pardo A, Jiménez W, Ginès P, Planas R, Lebrec D, Geuvel A, Elewaut A, Adler M, Arroyo V.
    J Hepatol; 1997 Mar 15; 26(3):614-20. PubMed ID: 9075669
    [Abstract] [Full Text] [Related]

  • 10. [Effect of captopril therapy on sodium and water excretion in patients with liver cirrhosis and ascites].
    Brunkhorst R, Wrenger E, Kühn K, Schmidt FW, Koch K.
    Klin Wochenschr; 1989 Aug 01; 67(15):774-83. PubMed ID: 2671477
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Normokalemic hyperaldosteronism in patients with resistant hypertension.
    Benchetrit S, Bernheim J, Podjarny E.
    Isr Med Assoc J; 2002 Jan 01; 4(1):17-20. PubMed ID: 11802302
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients.
    Gatta A, Angeli P, Caregaro L, Menon F, Sacerdoti D, Merkel C.
    Hepatology; 1991 Aug 01; 14(2):231-6. PubMed ID: 1860680
    [Abstract] [Full Text] [Related]

  • 16. Angiotensin-converting enzyme inhibitor and spironolactone combination therapy. New objectives in congestive heart failure treatment.
    Zannad F.
    Am J Cardiol; 1993 Jan 21; 71(3):34A-39A. PubMed ID: 8422003
    [Abstract] [Full Text] [Related]

  • 17. Renal effects of treatment with diuretics, octreotide or both, in non-azotemic cirrhotic patients with ascites.
    Kalambokis G, Economou M, Fotopoulos A, Bokharhii JA, Katsaraki A, Tsianos EV.
    Nephrol Dial Transplant; 2005 Aug 21; 20(8):1623-9. PubMed ID: 15886218
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effects of the oral converting enzyme inhibitor, SQ 14225, in a model of low cardiac output in dogs.
    Freeman RH, Davis JO, Williams GM, DeForrest JM, Seymour AA, Rowe BP.
    Circ Res; 1979 Oct 21; 45(4):540-5. PubMed ID: 225056
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.